Kronos Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kronos Bio, Inc. - overview
Established
2017
Location
San Mateo, CA, US
Primary Industry
Biotechnology
About
Founded in 2017 and headquartered in San Mateo, US, Kronos Bio, Inc. specializes in targeting gene regulation to create cancer treatments. The company has engaged in 4 deals, with its most recent deal being an IPO on October 8, 2020, raising USD 250. 00 mn by selling 13.
157 million shares at USD 19 per share on the Nasdaq. The CEO is Norbert Bischofberger. Kronos Bio, Inc. develops a range of cancer therapies aimed at inhibiting specific cellular pathways involved in tumor growth.
The company's core offerings focus on innovative drug candidates that target gene transcription and regulatory mechanisms, which are critical in cancer biology. Their products are marketed worldwide, catering to oncologists, hospitals, and research institutions that seek effective cancer treatment options.
Current Investors
Omega Funds, Vida Ventures, Bellco Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.